Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Advanced or Metastatic Melanoma
NCT03013101Phase 2Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in melanoma, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Status: unknown.
02
Drugs
toripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03013101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013101.